Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Quetiapine fumarate Clear all
Terminated Phase 2 Interventional Results available

Baclofen Effects on Smoking Urge and Withdrawal

NCT00257894
View directory record Official record
Conditions
Nicotine Use Disorder, Nicotine Dependence, Smoking, Tobacco Use Disorder
Interventions
Baclofen, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

NCT02431702
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M)
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 35 Years
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
34
States / cities
Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 4 Interventional

An Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence

NCT00223210
View directory record Official record
Conditions
Bipolar Disorder, Cocaine Dependence
Interventions
Quetiapine, PLacebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2012 · Synced Sep 28, 2026, 6:12 PM EDT
Terminated Phase 2Phase 3 Interventional

A Long-Term, Open-Label, Study on Schizophrenia

NCT01129674
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, Olanzapine, Aripiprazole, Risperidone, Quetiapine
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
42
States / cities
Little Rock, Arkansas • Escondido, California • Garden Grove, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 4 Interventional

A Comparison of Seroquel vs. Risperidone in Schizophrenia

NCT00034905
View directory record Official record
Conditions
Schizophrenia
Interventions
quetiapine fumarate vs risperidone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Not applicable Interventional

CATIE-Alzheimer's Disease Trial

NCT00015548
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Olanzapine, Quetiapine, Risperidone, Citalopram
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
34
States / cities
Tuscaloosa, Alabama • Irvine, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2015 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 4 Interventional Results available

NMDA Antagonists in Bipolar Depression

NCT01833897
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Standard of Care, Ketamine, D-cycloserine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2016 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 4 Interventional

Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

NCT00325689
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Quetiapine or Risperidone + Aripiprazole, Quetiapine or Risperidone + placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
48
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 4 Interventional Results available

Brain Imaging of Quetiapine Response in Anxious Depression

NCT00982345
View directory record Official record
Conditions
Major Depression
Interventions
quetiapine (Seroquel XR)
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 1 Interventional

A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

NCT05402111
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Quetiapine on Marijuana Withdrawal and Relapse

NCT00743366
View directory record Official record
Conditions
Marijuana Smoking
Interventions
Marijuana, Quetiapine, Placebo oral capsule
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 28, 2026, 6:12 PM EDT
Terminated Phase 4 Interventional Results available

Comparison of Quetiapine and Trazodone Treatment for Insomnia in Dually Diagnosed Veterans

NCT01662297
View directory record Official record
Conditions
Insomnia, Mental Health Disorder, Substance Use Disorder
Interventions
Quetiapine, Trazodone
Drug
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 3 Interventional

Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia

NCT00206128
View directory record Official record
Conditions
Schizophrenia
Interventions
Seroquel SR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
18
States / cities
Birmingham, Alabama • Anaheim, California • Cerritos, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 4 Interventional

Quetiapine Compared With Placebo in the Management of Fibromyalgia

NCT01458964
View directory record Official record
Conditions
Fibromyalgia
Interventions
Quetiapine
Drug
Lead sponsor
East Tennessee State University
Other
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Johnson City, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Sep 28, 2026, 6:12 PM EDT
Recruiting Phase 2 Interventional

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

NCT06591091
View directory record Official record
Conditions
Depression
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression

NCT00060489
View directory record Official record
Conditions
Bipolar Disorder, Depression, Bipolar
Interventions
SEROQUEL (quetiapine fumarate) Tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
27
States / cities
Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Quetiapine Pharmacotherapy for Cannabis Dependence

NCT01697709
View directory record Official record
Conditions
Cannabis Dependence
Interventions
Quetiapine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 4 Interventional

Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)

NCT00043849
View directory record Official record
Conditions
Dementia, Parkinson Disease
Interventions
Quetiapine
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 3 Interventional Results available

SGA-induced Metabolic Syndrome in Bipolar Youth

NCT01858948
View directory record Official record
Conditions
Bipolar Youth Treated With Second-generation Antipsychotics
Interventions
Omega, Placebo, Quetiapine fumarate
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 24, 2022 · Synced Sep 28, 2026, 6:12 PM EDT
Not listed Not applicable Interventional

Quetiapine Decreases Smoking in Patients With Chronic Schizophrenia

NCT00231101
View directory record Official record
Conditions
Smoking Behavior in Schizophrenia
Interventions
Quetiapine
Drug
Lead sponsor
Arthur P. Noyes Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2006 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 4 Interventional

Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence

NCT00223249
View directory record Official record
Conditions
Bipolar Disorder, Alcohol Abuse/Dependence
Interventions
Quetiapine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 3 Interventional

New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia

NCT00161018
View directory record Official record
Conditions
Schizophrenia
Interventions
Quetiapine, Risperidone, Fluphenazine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 4 Interventional

Quetiapine Treatment for Post-Traumatic Stress Disorder (PTSD)

NCT00237393
View directory record Official record
Conditions
PTSD
Interventions
Quetiapine, Placebo
Drug
Lead sponsor
Ralph H. Johnson VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Albuquerque, New Mexico • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2008 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 3 Interventional

Phase III/Seroquel SR Bipolar Depression Monotherapy - US

NCT00422214
View directory record Official record
Conditions
Affective Psychosis, Bipolar, Depression, Bipolar, Manic-Depressive Psychosis, Psychoses, Manic-Depressive
Interventions
Quetiapine fumarate (Seroquel) SR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
54
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Sep 28, 2026, 6:12 PM EDT